Figure 6. LY500307 reduces GBM progression and induces apoptosis in vivo.
(A) U251 GBM-luc cells were implanted intracranially into the right striatum of nude mice. The mice were then randomized to either the control or the treatment group and received either vehicle or LY500307 (5 mg/kg body weight/day), respectively, for 28 days. Tumor growth in terms of luciferase intensity was measured using Xenogen IVIS imaging (n = 5). (B) Mouse brains collected from both the control and LY500307-treated mice were fixed in formalin and subjected to immunohistochemical staining for Ki-67. For quantitation, Ki-67-positive cells from five different fields were counted and plotted as histogram. (C) Brain sections were subjected to a TUNEL assay, and the number of TUNEL-positive cells was counted in five different fields and plotted as histogram. DAPI was used to visualize the nuclei. Data are represented as mean ± SE. *p < 0.05, **p < 0.01, ***p < 0.001.